Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vascular Pathophysiology in Obstructive Sleep Apnea
NCT00214084 · University of Wisconsin, Madison · NA · withdrawn · last registry update 2015-10-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, University of Wisconsin, Madison |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against XDH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-10-03Results posted on the registry: University of Utah, Febuxostat + Placebo (NCT01350388)
- 2016-08-18Results posted on the registry: Ardea Biosciences, Inc., Lesinurad + Lesinurad (NCT01510158)
- 2016-08-15Phase 3 first posted: Ain Shams University, Febuxostat + Placebo (NCT02866214)
- 2016-05-26Results posted on the registry: Ardea Biosciences, Inc., Lesinurad + Lesinurad (NCT01510769)
- 2016-05-26Results posted on the registry: Ardea Biosciences, Inc., Lesinurad + Lesinurad (NCT01493531)
- 2016-04-29Results posted on the registry: Takeda, Febuxostat XR + Maalox Advance Regular Strength liquid (NCT02382640)
- 2016-04-27Results posted on the registry: Takeda, Febuxostat XR (NCT02374164)
- 2016-04-13Results posted on the registry: Takeda, Febuxostat + Febuxostat placebo (NCT01763996)
- 2016-02-09Results posted on the registry: Johns Hopkins University, Allopurinol + Placebo (NCT00181155)
- 2016-02-03Results posted on the registry: Xijing Hospital, Febuxostat + Allopurinol (NCT02082769)
- 2016-01-05Results posted on the registry: University of Michigan, ORAL ANTIOXIDANT (NCT00116207)
- 2015-09-17Results posted on the registry: Paul N. Hopkins, Febuxostat + Placebo (NCT01328769)
- 2015-08-31Results posted on the registry: Takeda, Febuxostat + Placebo (NCT01496469)
- 2015-08-27Phase 3 first posted: Hospices Civils de Lyon, 2 capsules of allopurinol 150 mg daily for 3 month + 2 capsules of lactose daily for 3 month (NCT02533648)
- 2015-05-27Also stopped (terminated): Stephen McSwiggan, Allopurinol + Allopurinol (NCT01457820)
- 2015-05-15Results posted on the registry: Masonic Cancer Center, University of Minnesota, Allopurinol + Fludarabine (NCT01464359)
- 2015-01-05Results posted on the registry: 59th Medical Wing, allopurinol + Placebo (sugar pill) (NCT01988402)
- 2014-12-01Results posted on the registry: TWi Biotechnology, Inc., Placebo + AC-201 (NCT01712204)
- 2014-11-03Results posted on the registry: Menarini Group, Febuxostat + Allopurinol (NCT01724528)
- 2014-10-22Results posted on the registry: Alliance for Clinical Trials in Oncology, filgrastim + rituximab (NCT00039130)
- 2014-10-20Results posted on the registry: Duke University, allopurinol + sugar pill (NCT00987415)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision